Y-mAbs Therapeutics (YMAB) News Today

Acadian Asset Management LLC decreased its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 24.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 602,314 shares of the com

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has earned an average rating of "Hold" from the seven brokerages that are presently covering the firm, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation and five have issued a buy recommendat

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Up to $12.07

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 2.5%

Truist Financial began coverage on shares of Y-mAbs Therapeutics in a research note on Friday. They set a "buy" rating and a $21.00 price target for the company.

Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) have been assigned a consensus recommendation of "Hold" from the six brokerages that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating and four have assigned a

Los Angeles Capital Management LLC lessened its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 64.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 127,551 shares of the company's stock after selling 228,979 shares

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) insider Thomas Gad sold 35,000 shares of the company's stock in a transaction on Monday, June 10th. The stock was sold at an average price of $12.03, for a total value of $421,050.00. Following the transaction, the insider now directly owns 197,681 shares in the company, valued at approximately $2,378,102.43. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Campbell & CO Investment Adviser LLC bought a new position in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 82,391 shares of the company's stock, valued at appr

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) CFO Bo Kruse sold 31,371 shares of the business's stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Hold" by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommen

Y-mAbs Therapeutics (NASDAQ:YMAB) Sees Unusually-High Trading Volume

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 3%

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 7.5% Higher

HC Wainwright upped their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Monday.

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 6.8%

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21

Sapient Capital LLC purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 43,700 shares of the company's stock, valued at approximately $298,000. Sapient Ca

Y-mAbs Therapeutics (NASDAQ:YMAB) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=590317)

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 7%

Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating to

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.3%

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%

Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 5.9%

Denali Advisors LLC lessened its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 80.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,400 shares of the company's stock after

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 3.9% Higher

Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4.3%